01—Abstract
Summary
Summary of the 8-K filed February 15, 2024. Cited figures are marked; the original filing is the authoritative source.
DexCom, Inc. (DXCM) has entered into a Warrant Termination Agreement with Bank of America, N.A.
(BofA) on February 13, 2024, to terminate outstanding warrants related to its 0.75%a Convertible Senior Notes due 2023. These warrants were originally issued in connection with the convertible notes and associated hedge and warrant transactions with BofA and JPMorgan Chase Bank (JPM). The termination agreement will resolve approximately 10.3 million shares of common stock warrants held by BofA.
In exchange for the warrant termination, DexCom will issue shares of its common stock to BofA. The number of shares will be determined by the daily volume-weighted average price of DexCom's common stock over a specified averaging period expected to conclude in the first quarter of 2024. This transaction is being conducted under an exemption from registration, implying it is not being offered to the public and is intended to simplify the company's capital structure and remove potential future dilution from these specific warrants.
02—Key points
Key Highlights
- DexCom terminates a material definitive agreement concerning outstanding warrants with Bank of America.
- The agreement specifically addresses warrants originally tied to the 0.75% Convertible Senior Notes due 2023.
- Approximately 10.3 million shares of DexCom's common stock, subject to anti-dilution adjustments, are involved in this termination.
- DexCom will issue shares of its common stock to Bank of America as consideration for the warrant termination.
- The number of shares to be issued will be based on a volume-weighted average price (VWAP) during a defined averaging period.
- The averaging period is expected to conclude in the first quarter of 2024.
- The issuance of shares is being made under an exemption from registration (Section 4(a)(2) of the Securities Act of 1933), indicating a private transaction.
03—Questions
Frequently Asked Questions
What is the primary purpose of this warrant termination agreement?
The primary purpose is to terminate outstanding warrants held by Bank of America that were related to DexCom's now-matured 0.75% Convertible Senior Notes due 2023. This simplifies the company's outstanding capital obligations and removes potential future dilution from these specific warrants.
How many shares of DexCom's common stock are involved?
The termination agreement covers warrants for approximately 10.3 million shares of DexCom's common stock, as adjusted for past stock splits.
How will DexCom compensate Bank of America for terminating the warrants?
DexCom will issue shares of its common stock to Bank of America. The exact number of shares will be calculated based on the daily volume-weighted average price (VWAP) of DexCom's common stock during a specific averaging period.
When will the shares be issued, and is this a public offering?
The averaging period to determine the number of shares is expected to be completed in the first quarter of 2024. The shares are being issued under an exemption from registration (Section 4(a)(2) of the Securities Act of 1933), meaning it is a private transaction and not a public offering.
04—Continue